RAS

VTB Bank announces RAS financial results (standalone) for 2021

Retrieved on: 
Monday, January 17, 2022 - 11:02am

VTB Bank (PJSC) (hereinafter referred to as the Bank) publishes its standalone key RAS financial results for December and twelve months of 2021.

Key Points: 
  • VTB Bank (PJSC) (hereinafter referred to as the Bank) publishes its standalone key RAS financial results for December and twelve months of 2021.
  • VTB Bank earned a record high net profit in 2021 in the amount of RUB 242.6 billion.
  • The Bank's RAS results are highly correlated with VTB Group's IFRS results, and the figures we publish are the indicators of the Group's excellent results for the year under IFRS."
  • The reported financial indicators are preliminary; hence, they can be supplemented and changed in the process of preparation of publishable financial reports of VTB Bank.

Sberbank: Sber earned RUB1,237 trn in net profit for 2021 (X1.7), excluding the effect of subsequent events

Retrieved on: 
Friday, January 14, 2022 - 8:02am

SberBank releases Financial Highlights for 2021, excluding the effect of subsequent events (under RAS, non-consolidated)

Key Points: 
  • SberBank releases Financial Highlights for 2021, excluding the effect of subsequent events (under RAS, non-consolidated)
    The numbers are calculated in accordance with SberBank's internal methodology.
  • The effect of subsequent events is included in the numbers as of January 1, 2021 but excluded from the numbers as of January 1, 2022.
  • The Bank earned RUB1,237 trn in net profit for the year, excluding the effect of subsequent events.
  • As a result, net profit for the year 2021 exceeded RUB1.2 trn with ROE close to 25%."

Diamond Equity Research Issues Update on Blue Star Foods Corp.

Retrieved on: 
Thursday, January 13, 2022 - 2:30pm

Miami, FL, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (NASDAQ:BSFC) (Blue Star or BSFC), an integrated Environmental, Social, and Governance (ESG) seafood company, today announced that Diamond Equity Research has issued an updated research report on Blue Star Food Corp.s operations.

Key Points: 
  • Miami, FL, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (NASDAQ:BSFC) (Blue Star or BSFC), an integrated Environmental, Social, and Governance (ESG) seafood company, today announced that Diamond Equity Research has issued an updated research report on Blue Star Food Corp.s operations.
  • AboutBlue Star Foods Corp.
    Blue Star Foods Corp. is an integrated ESG seafood company that processes, packages and sells high-value seafood products.
  • Diamond Equity Research is a leading equity research and corporate access firm focused on small capitalization companies.
  • Diamond Equity Research LLC is being compensated by Blue Star Foods Corp. (the "Company") for producing the research materials herein regarding the Company and its securities, which is meant to subsidize the high cost of creating the report and monitoring the security, however the views in the report reflect that of Diamond Equity Research.

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation

Retrieved on: 
Thursday, January 13, 2022 - 12:30pm

PALO ALTO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced a non-exclusive clinical collaboration with Amgen Inc. (Amgen) to evaluate the combination of BBP-398, a potentially best-in-class SHP2 inhibitor, with LUMAKRAS® (sotorasib), a KRASG12C inhibitor, in patients with advanced solid tumors with the KRAS G12C mutation.

Key Points: 
  • Under the terms of the non-exclusive collaboration, BridgeBio will sponsor the study and Amgen will provide a global supply of LUMAKRAS.
  • BBP-398 is a potent small-molecular inhibitor of SHP2 developed in collaboration with The University of Texas MDAnderson Cancer Centers Therapeutics Discovery division.
  • By combining SHP2 inhibition with KRASG12C inhibition in patients with the KRAS G12C mutation, there is potential that the investigational combination could prevent oncogenesis and overactive cellular proliferation.
  • BBP-398, as a monotherapy or in combination with other targeted therapies, could potentially be a promising therapy for patients with the KRAS G12C mutation.

Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers

Retrieved on: 
Tuesday, January 11, 2022 - 12:00pm

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcoming catalysts to support its lead compound VS-6766 in 2022.

Key Points: 
  • Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcoming catalysts to support its lead compound VS-6766 in 2022.
  • Initiate and complete dose-finding portions of RAMP 203 (KRAS G12C NSCLC VS-6766 + LUMAKRASTM (sotorasib)) and RAMP 204 (KRAS G12C NSCLC VS-6766 + adagrasib) combination trials.
  • Expand investigator-initiated trial program to include signal-finding studies in other tumor types, including melanoma, breast and colorectal cancers.
  • Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer.

Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones

Retrieved on: 
Monday, January 10, 2022 - 12:00pm

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2022 milestones in conjunction with its presentation at the 40th Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate update and highlighted key 2022 milestones in conjunction with its presentation at the 40th Annual J.P. Morgan Healthcare Conference.
  • Deciphera is well-positioned as we enter 2022 with multiple high-value clinical programs and a successful commercial franchise in QINLOCK, all generated by our proven and productive research engine, said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals.
  • In 2022, the Company seeks to achieve the following milestones:
    Execute on the commercial launch of QINLOCK in fourth-line GIST in Germany.
  • Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.

Corel’s Creative and Productivity Solutions Earn Top Marks in 22 G2 Winter 2022 Grid Reports

Retrieved on: 
Thursday, January 6, 2022 - 4:03pm

Corels collection of creative, collaborative, and productivity products are uniquely positioned to meet these needs, and our solutions are constantly evolving to empower teams to do their best work.

Key Points: 
  • Corels collection of creative, collaborative, and productivity products are uniquely positioned to meet these needs, and our solutions are constantly evolving to empower teams to do their best work.
  • Collectively, the portfolio received 22 notable placements in the Winter 2022 Grid Reports.
  • Leading mind mapping software, MindManager, was recognized as a High Performer in the overall G2 Grid for Mind Mapping as well as the G2 Grid for Mind Mapping specific to small businesses.
  • Painter, Corels powerful digital painting software, received recognition as a High Performer in the G2 Small-Business Grid Report for Drawing.

NaturalShrimp Electrocoagulation Technology Shown to Reduce Nitrites in Recirculating Aquaculture Systems

Retrieved on: 
Thursday, January 6, 2022 - 1:30pm

The team demonstrated that its patented electrocoagulation (EC) technology can reduce nitrites without the need for a biofilter in a recirculating aquaculture system (RAS) filtration system.

Key Points: 
  • The team demonstrated that its patented electrocoagulation (EC) technology can reduce nitrites without the need for a biofilter in a recirculating aquaculture system (RAS) filtration system.
  • In a recirculating aquaculture system (RAS), the filtration system must continually remove ammonia to effectively treat water and hold production tonnages of stock.
  • The patented electrocoagulation (EC) technology has proven its ability to remove ammonia within a recirculating aquaculture system (RAS) before it converts to nitrites.
  • The NaturalShrimp technical team has now discovered that the EC system could also reduce nitrites without the need for a biofilter in RAS that might experience a buildup of nitrites.

Blue Star Foods RAS Division Announces Key H2-2021 Operating Metrics For Existing Production Facility

Retrieved on: 
Wednesday, January 5, 2022 - 1:25pm

We are very pleased with the consistency of the production, as well as the quality of the fish being created said John Keeler, CEO of Blue Star Foods Corp.

Key Points: 
  • We are very pleased with the consistency of the production, as well as the quality of the fish being created said John Keeler, CEO of Blue Star Foods Corp.
  • He further continued, We encourage investors in the space to look at our operating metrics and compare them to other RAS farm projects.
  • Our focus is to continue this level of production at this first facility, as we build out our next, larger, 1,500 metric ton facility.
  • About Blue Star Foods Corp.
    Blue Star Foods Corp. is an integrated ESG seafood company that processes, packages and sells high-value seafood products.

2021 Pipeline Insights into Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 5, 2022 - 1:16pm

The "Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Protein Tyrosine Phosphatase Non Receptor Type 11 Antagonists - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about 7+ companies and 8+ pipeline drugs in Protein tyrosine phosphatase non receptor type 11 antagonists pipeline landscape.
  • The therapies under development are focused on novel approaches to treat/improve Protein tyrosine phosphatase non receptor type 11 antagonists.
  • What are the clinical studies going on for Protein tyrosine phosphatase non receptor type 11 antagonists and their status?